Validation of an indirect in-house ELISA using synthetic peptides to detect antibodies anti-gp90 and gp45 of the equine infectious anaemia virus

Serodiagnosis of equine infectious anemia by indirect ELISA based on a novel synthetic peptide derived from gp45 glycoprotein

The transmembrane glycoprotein gp45 (implicated in virus-equine B lymphocyte binding and in subsequent infection) is an important protein used as an antigen in the serological diagnosis of equine infectious anemia, but synthetic peptides derived from its structure are not. Consequently, the present study aimed to determine the diagnostic performance of the Bio-AIELAB immunoassay (novel synthetic peptide P05/gp45) in comparison with a similar commercial assay (ELISA EIA, VMRD Inc, USA) and with the gold standard (AGID, LABIOFAM, Cuba). A total of 365 samples of sera from naturally infected Cuban horses (positive: 179, and negative: 186) were investigated by Bio-AIELAB and AGID, of which 299 (positive: 147, and negative: 152) were analysed by ELISA EIA. The performance indicators used in all cases were: relative diagnostic sensitivity and specificity, positive and negative predictive values, as well as concordance according to the Kappa index. The Bio-AIELAB system obtained the best performance in sensitivity (99.44%, 178/179), specificity (95.16%, 177/186) and concordance (Kappa index: 0.94) with respect to ELISA EIA test. Based on the above elements, Bio-AIELAB could be a promising candidate for use in equine infectious anemia surveillance programs in combination with the AGID test.

Development and evaluation of a test strip for the rapid detection of antibody against equine infectious anemia virus

Equine infectious anemia (EIA) is a contagious disease of horses caused by the equine infectious anemia virus (EIAV). The clinical signs at the acute phase include intermittent high fever, thrombocytopenia, hemorrhage, edema, and anemia. The clinical signs at chronic and relapsing subclinical levels include emaciation and progressive weakness. Surviving horses become lifelong carriers because of the integration of the viral genome into that of the host, and these horses can produce and transmit the virus to other animals. This increases the difficulty of imposing practical control measures to prevent epidemics of this disease. Serological tests measuring the antibodies in equine sera are considered to be a reliable tool for the long-term monitoring of EIA. However, the standard serological tests for EIV either have low sensitivity (e.g., agar gel immunodiffusion test, AGID) or are time consuming to perform (e.g., ELISA and western blotting). The development of a rapid and simple method for detecting the disease is therefore critical to control the spread of EIA. In this study, we designed and developed a colloidal gold immunochromatographic (GICG) test strip to detect antibodies against EIAV based on the double-antigen sandwich. Both the p26 and gp45 proteins were used as the capture antigens, which may help to improve the positive detection rate of the strip. We found that the sensitivity of the test strip was 8 to 16 times higher than those of two commercially available ELISA tests and 128 to 256 times higher than AGID, but 8 to 16 times lower than that of western blotting. The strip has good specificity and stability. When serum samples from experimental horses immunized with the attenuated EIAV vaccine (n = 31) were tested, the results of the test strip showed 100% coincidence with those from NECVB-cELISA and 70.97% with AGID. When testing clinical serum samples (n = 1014), the test strip surprisingly provided greater sensitivity and a higher number of "true positive" results than other techniques. Therefore, we believe that the GICG test strip has demonstrated great potential in the field trials as a simple and effective tool for the detection of antibodies against EIAV. KEY POINTS: • A colloidal gold immunochromatographic (GICG) fast test strip was developed with good specificity, sensitivity, stability, and repeatability • The test strip can be used in point-of-care testing for the primary screening of EIAV antibodies • Both the p26 and gp45 proteins were used as the capture antigens, giving a high positive detection rate in the testing of experimentally infected animal and field samples.